Targeting pancreatic cancer (PC) via anti-fibrotic NID2 therapy and Gemcitabine/Abraxane chemotherapy treatment: stratifying PC therapy

Pancreatic Cancer

Professor Paul Timpson

The Garvan Institute of Medical Research (NSW)


2024 - 2027

The Research

Due to surgically unresectable, advanced disease being present at the time of diagnosis, pancreatic cancer is one of the most lethal forms of human cancer, with >90% of patient deaths occurring within 1 year of diagnosis. Systemic therapies are largely ineffective for inoperable disease. Recent work however at our Institute has shown that a number of patients harbour high levels of fibrosis, make them exquisitely sensitive to anti-fibrotic therapy. This may be enhanced by combination with gemcitabine/Abraxane and can only be seen when looking in live tissue.  

Consequently, the development of more effective strategies to maximise this new opportunity in pancreatic cancer is urgently required.


Similar research

No items found.